Enlivex Ltd. announced FDA clearance of its IND application for a global Phase 2b trial of Allocetra in moderate-to-severe age-related symptomatic primary knee osteoarthritis, following positive Phase 1/2a data in 134 patients showing robust, durable treatment effects. This marks the company's first regulatory approval under its dual-engine value creation model.
Key takeaways
FDA cleared IND for Phase 2b multicenter randomized double-blind placebo-controlled trial of Allocetra via intra-articular injections
Trial evaluates efficacy and safety in moderate-to-severe age-related knee OA patients, with endpoints including pain, function at 3-6 months
Follows Phase 1/2a trial in 134 patients with statistically significant effects lasting at least 6 months, stronger in older patients
Knee OA affects >32 million Americans today, projected 78 million by 2040
First clearance after implementing dual-engine model: clinical-stage longevity program with prediction markets treasury strategy